Patents Assigned to Centocor, Inc.
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20060018907
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: July 14, 2005
    Publication date: January 26, 2006
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel, David Shealy
  • Method of treating psoriasis using human anti-TNF antibodies and fragments
    Publication number: 20060013816
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: June 29, 2005
    Publication date: January 19, 2006
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
    Publication number: 20050260201
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: February 7, 2005
    Publication date: November 24, 2005
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel, Bernard Scallon
  • Methods of treating psoriasis using anti-TNF receptor fusion proteins
    Publication number: 20050255104
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: February 7, 2005
    Publication date: November 17, 2005
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel, Bernard Scallon
  • Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20050249735
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: December 13, 2004
    Publication date: November 10, 2005
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel, David Shealy
  • Anti-IL-12 antibodies and compositions thereof
    Patent number: 6902734
    Abstract: The present invention relates to at least one anti-IL-12 antibody, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: June 7, 2005
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Chemically defined medium for cultured mammalian cells
    Patent number: 6900056
    Abstract: The present invention relates to methods and compositions for chemically defined media for growth of mammalian cells for production of commercially useful amounts of expressed proteins.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: May 31, 2005
    Assignee: Centocor, Inc.
    Inventors: ChiChang Lee, Celia Ly, Gordon Moore, Robert Perkinson
  • Compounds having reduced immunogenicity and a method of reducing the immunogenicity of compounds
    Publication number: 20050079183
    Abstract: Reduced-immunogenic fusion compounds are disclosed. The fusion compounds of the invention comprise immunogenic compounds linked to auto-antigenic sequences which render the compound less immunogenic. In addition, a method of reducing the immunogenicity of an immunogenic compound is disclosed. The method comprises linking an auto-antigenic sequence to an otherwise immunogenic compound. Recombinant nucleotide sequence encoding auto-antigenic sequences are also disclosed.
    Type: Application
    Filed: September 2, 2003
    Publication date: April 14, 2005
    Applicant: Centocor, Inc.
    Inventors: Robert Jordan, Carrie Wagner, David Knight
  • Methods of treating carcinoma using anti-TNF antibodies and peptides
    Publication number: 20050074454
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: September 30, 2004
    Publication date: April 7, 2005
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Cloning and expression of HTLV-III DNA
    Patent number: 6858712
    Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 22, 2005
    Assignees: The United States of America as represented by the Department of Health and Human Services, Centocor, Inc.
    Inventors: Nancy T. Chang, Robert C. Gallo, Flossie Wong-Staal
  • Methods of treating carcinoma using anti-TNF antibodies and fragments thereof
    Publication number: 20050037008
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: September 30, 2004
    Publication date: February 17, 2005
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Patent number: 6835823
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: December 28, 2004
    Assignees: New York University, Centocor, Inc.
    Inventors: Jumming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-TNF antibodies and peptides of human necrosis factor
    Patent number: 6790444
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: September 14, 2004
    Assignees: New York University Medical Center, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20040138427
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: February 6, 2004
    Publication date: July 15, 2004
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghraveb, David Knight, Scott Siegel
  • Anti-TNF antibodies and peptides of human tumor necrosis factor
    Publication number: 20040120952
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: August 8, 2003
    Publication date: June 24, 2004
    Applicant: Centocor, Inc
    Inventors: David M. Knight, David J. Shealy
  • Methods of treating neurodegenerative inflammation with chimeric anti-TNF antibodies
    Publication number: 20040115200
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: September 19, 2003
    Publication date: June 17, 2004
    Applicants: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Method of reducing the immunogenicity of compounds
    Patent number: 6652863
    Abstract: Reduced-immunogenic fusion compounds are disclosed. The fusion compounds of the invention comprise immunogenic compounds linked to auto-antigenic sequences which render the compound less immunogenic. In addition, a method of reducing the immunogenicity of an immunogenic compound is disclosed. The method comprises linking an auto-antigenic sequence to an otherwise immunogenic compound. Recombinant nucleotide sequences encoding auto-antigenic sequences are also disclosed.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: November 25, 2003
    Assignee: Centocor, Inc.
    Inventors: Robert E. Jordan, Carrie Lynne Wagner, David M. Knight
  • Methods of treating ulcerative colitis with chimeric anti-TNF antibodies
    Publication number: 20030198641
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-&agr; (TNF&agr;) and are useful in vivo diagnosis and therapy of a number of TNF&agr;-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: March 4, 2003
    Publication date: October 23, 2003
    Applicants: New York University, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghraveb, David Knight, Scott Siegel
  • Methods for sustained drug delivery and compositions useful therefor
    Publication number: 20030198633
    Abstract: Methods for sustained delivery of a therapeutic agent to the circulation of a patient are disclosed. Also disclosed are methods of preparing bioconjugates for sustained delivery of a therapeutic agent to the circulation of a patient.
    Type: Application
    Filed: April 2, 2003
    Publication date: October 23, 2003
    Applicant: Centocor, Inc.
    Inventors: Robert E. Jordan, David M. Knight
  • Detection of HIV-1 DNA
    Patent number: 6610476
    Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 26, 2003
    Assignees: The United States of America as represented by the Department of Health and Human Services, Centocor, Inc.
    Inventors: Nancy T. Chang, Robert C. Gallo, Flossie Wong-Staal